Two months after giving birth to their daughter, Jayla, Shelly Balboa and her partner, Joseph, noticed the left side of their ...
Photographers Kevin Black and Dave Clements have released the third of their three-volume "Raising A Hand" series that raises money for Rett syndrome research.
Investor's Business Daily on MSN1d
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A WeekNeurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Coleen Rooney became emotional in the I'm A Celebrity... Get Me Out Of Here! camp as she reflected on the death of her little ...
Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...
Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback